JP6709786B2 - Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体 - Google Patents

Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体 Download PDF

Info

Publication number
JP6709786B2
JP6709786B2 JP2017530208A JP2017530208A JP6709786B2 JP 6709786 B2 JP6709786 B2 JP 6709786B2 JP 2017530208 A JP2017530208 A JP 2017530208A JP 2017530208 A JP2017530208 A JP 2017530208A JP 6709786 B2 JP6709786 B2 JP 6709786B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
methyl
solvate
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017530208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537114A5 (cg-RX-API-DMAC10.html
JP2017537114A (ja
Inventor
ペン，ジュロン
コスタンゾ，マイケル，ジョン
グレコ，マイケル，ニコラス
グリーン，マイケル，アラン
ワイルド，ビクトリア，リン
チャン，ドン
Original Assignee
ベータ ファーマ，インコーポレイテッド
ベータ ファーマ，インコーポレイテッド
ベータ ファーマ（シャンハイ）カンパニー，リミテッド
ベータ ファーマ（シャンハイ）カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベータ ファーマ，インコーポレイテッド, ベータ ファーマ，インコーポレイテッド, ベータ ファーマ（シャンハイ）カンパニー，リミテッド, ベータ ファーマ（シャンハイ）カンパニー，リミテッド filed Critical ベータ ファーマ，インコーポレイテッド
Publication of JP2017537114A publication Critical patent/JP2017537114A/ja
Publication of JP2017537114A5 publication Critical patent/JP2017537114A5/ja
Application granted granted Critical
Publication of JP6709786B2 publication Critical patent/JP6709786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017530208A 2014-12-11 2015-12-11 Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体 Active JP6709786B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090869P 2014-12-11 2014-12-11
US62/090,869 2014-12-11
US201562166883P 2015-05-27 2015-05-27
US62/166,883 2015-05-27
PCT/US2015/065286 WO2016094821A2 (en) 2014-12-11 2015-12-11 Substituted 2-anilinopyrimidine derivatives as egfr modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020090467A Division JP7181558B2 (ja) 2014-12-11 2020-05-25 Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2017537114A JP2017537114A (ja) 2017-12-14
JP2017537114A5 JP2017537114A5 (cg-RX-API-DMAC10.html) 2019-01-17
JP6709786B2 true JP6709786B2 (ja) 2020-06-17

Family

ID=56108380

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530208A Active JP6709786B2 (ja) 2014-12-11 2015-12-11 Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
JP2020090467A Active JP7181558B2 (ja) 2014-12-11 2020-05-25 Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020090467A Active JP7181558B2 (ja) 2014-12-11 2020-05-25 Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体

Country Status (17)

Country Link
US (2) US10590111B2 (cg-RX-API-DMAC10.html)
EP (1) EP3229798A4 (cg-RX-API-DMAC10.html)
JP (2) JP6709786B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170098865A (cg-RX-API-DMAC10.html)
CN (3) CN112375067B (cg-RX-API-DMAC10.html)
AU (1) AU2015360360B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017012272A2 (cg-RX-API-DMAC10.html)
CA (1) CA2970185C (cg-RX-API-DMAC10.html)
CO (1) CO2017006962A2 (cg-RX-API-DMAC10.html)
EA (1) EA036453B1 (cg-RX-API-DMAC10.html)
HK (1) HK1245634A1 (cg-RX-API-DMAC10.html)
IL (1) IL252554A0 (cg-RX-API-DMAC10.html)
MX (1) MX382869B (cg-RX-API-DMAC10.html)
PH (1) PH12017501057A1 (cg-RX-API-DMAC10.html)
SG (2) SG10201909060SA (cg-RX-API-DMAC10.html)
TW (1) TWI618704B (cg-RX-API-DMAC10.html)
WO (1) WO2016094821A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143131A (ja) * 2014-12-11 2020-09-10 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
BR112018072887A2 (pt) 2016-05-11 2019-03-06 Beta Pharma, Inc. método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
AU2017285448B2 (en) * 2016-06-17 2021-02-04 Beta Pharma, Inc. Pharmaceutical salts of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
CN106243044A (zh) * 2016-06-30 2016-12-21 浙江大学 含卤代丙烯酰胺侧链的嘧啶类衍生物及制备和应用
JP6740452B2 (ja) * 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
BR112019026483A2 (pt) * 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
CN109503573A (zh) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2-取代苯胺基嘧啶衍生物及其用途
CN107935995A (zh) * 2017-11-28 2018-04-20 中山大学 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
PT3806898T (pt) * 2018-06-18 2025-12-02 UCB Biopharma SRL Antagonista de gremlin-1 para utilização no tratamento do cancro
SG11202102377YA (en) 2018-09-10 2021-04-29 Mirati Therapeutics Inc Combination therapies
EP4034121A4 (en) * 2019-09-23 2023-10-18 Beta Pharma, Inc. TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20240063865A (ko) * 2021-07-13 2024-05-10 아세아 테라퓨틱스 인코포레이티드 헤테로사이클릭 화합물 및 이의 용도
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
JP2025516171A (ja) 2022-04-28 2025-05-27 アストラゼネカ・アクチエボラーグ 縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
CA3259492A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288019B6 (sk) 1999-12-24 2012-11-05 Aventis Pharma Limited Azaindoles derivatives, their use and pharmaceutical composition containing thereof
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
CA2670375A1 (en) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
WO2010059711A1 (en) 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
AU2012250517B2 (en) * 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
PL3009431T3 (pl) * 2011-07-27 2018-02-28 Astrazeneca Ab Pochodne 2-(2,4,5-podstawionej-anilino) pirymidyny jako modulatory egfr użyteczne do leczenia nowotworu
JP6469567B2 (ja) * 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
PH12016502453B1 (en) 2014-06-19 2022-11-23 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
WO2016029839A1 (zh) 2014-08-25 2016-03-03 四川海思科制药有限公司 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
SG10201909060SA (en) 2014-12-11 2019-11-28 Beta Pharma Inc Substituted 2-anilinopyrimidine derivatives as egfr modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143131A (ja) * 2014-12-11 2020-09-10 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
JP7181558B2 (ja) 2014-12-11 2022-12-01 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体

Also Published As

Publication number Publication date
CO2017006962A2 (es) 2017-10-20
TWI618704B (zh) 2018-03-21
CN112457298A (zh) 2021-03-09
SG11201704685TA (en) 2017-07-28
SG10201909060SA (en) 2019-11-28
IL252554A0 (en) 2017-07-31
MX2017007664A (es) 2018-01-23
AU2015360360A1 (en) 2017-06-08
WO2016094821A3 (en) 2016-08-25
US20200216421A1 (en) 2020-07-09
CN112457298B (zh) 2024-05-07
JP2017537114A (ja) 2017-12-14
CN108024993A (zh) 2018-05-11
PH12017501057A1 (en) 2018-03-05
EA036453B1 (ru) 2020-11-12
US20170362203A1 (en) 2017-12-21
US10590111B2 (en) 2020-03-17
HK1245634A1 (zh) 2018-08-31
CA2970185A1 (en) 2016-06-16
EP3229798A2 (en) 2017-10-18
BR112017012272A2 (pt) 2018-01-30
MX382869B (es) 2025-03-13
CN112375067A (zh) 2021-02-19
CN108024993B (zh) 2020-11-06
EA201790921A1 (ru) 2017-12-29
KR20170098865A (ko) 2017-08-30
TW201632512A (zh) 2016-09-16
EP3229798A4 (en) 2018-05-30
JP7181558B2 (ja) 2022-12-01
JP2020143131A (ja) 2020-09-10
US11414401B2 (en) 2022-08-16
CN112375067B (zh) 2024-03-15
CA2970185C (en) 2023-10-17
AU2015360360B2 (en) 2020-06-25
WO2016094821A2 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
JP6709786B2 (ja) Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
JP6431593B6 (ja) ピリジニルアミノピリミジン誘導体、その製造方法、および用途
RU2656591C2 (ru) Модуляторы протеин-тирозинкиназы и способы их применения
JP6101341B2 (ja) 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用
JP7337395B2 (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用
CN105377835A (zh) 酪氨酸蛋白激酶调节剂及其应用方法
CN108503627A (zh) 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用
JP2025081599A (ja) Ｅｇｆｒキナーゼを阻害する化合物、調製方法、及びその使用
CN103936762A (zh) 吗啉并喹啉类化合物，其制备方法和用途
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
JP6943886B2 (ja) 縮合ピリミジノピペリジン誘導体、ならびにその製造方法および適用
OA18657A (en) Substituted 2-anilinopyrimidine derivatives as EGFR modulators.
HK40081466A (en) Efgr inhibitor, preparation method therefor, and application thereof
KR20160030296A (ko) 단백질 티로신 키나제 조절자 및 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200525

R150 Certificate of patent or registration of utility model

Ref document number: 6709786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250